The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
Irene M. Ghobrial
Consultant or Advisory Role - Novartis
Morie A. Gertz
No relevant relationships to disclose
Betsy LaPlant
No relevant relationships to disclose
John Kelly Camoriano
No relevant relationships to disclose
Suzanne R. Hayman
No relevant relationships to disclose
Martha Lacy
No relevant relationships to disclose
Stacey Chuma
No relevant relationships to disclose
Brianna Harris
No relevant relationships to disclose
Erica Boswell
No relevant relationships to disclose
Ranjit Banwait
No relevant relationships to disclose
Patricia Sheehy
No relevant relationships to disclose
Stephen Maxted Ansell
No relevant relationships to disclose
Daniel J DeAngelo
Consultant or Advisory Role - Novartis
Angela Dispenzieri
No relevant relationships to disclose
Leif Bergsagel
No relevant relationships to disclose
Craig B. Reeder
No relevant relationships to disclose
Kenneth Carl Anderson
Consultant or Advisory Role - Novartis
Paul Gerard Guy Richardson
Consultant or Advisory Role - Novartis
Steven P. Treon
Consultant or Advisory Role - Novartis
Thomas E. Witzig
Consultant or Advisory Role - Novartis (U)